Money Talks | Business and finance

How Britain’s growth problem became a crisis

Our podcast on markets, the economy and business. This week, how broken is Britain?

Britain is in a 17-year funk. A series of crises—some global and some homemade—have battered the British economy since 2008. GDP growth has been cut in half in the years since the global financial crisis, and after inflation, wages have barely budged either. Now, long-term government bond yields have risen to their highest levels in a quarter of a century, casting doubt on the new government’s plans for spending. So, just how broken is Britain?

Hosts: Mike Bird and Ethan Wu. Guests: The Economist’s Archie Hall; Paul Johnson, director of the Institute for Fiscal Studies; and Bank of England rate-setter Catherine Mann.

More from Podcasts

Podcast Editor’s Picks

The promise of vaccines for cancer

A handpicked article read aloud from the latest issue of The Economist

Podcast The Intelligence

How India is grappling with climate-change adaptation

Also on the daily podcast: our series The World Ahead looks at the (few) constraints on Trump and robots come to vineyards


A varied group of people engages in breathing exercises, representing diverse backgrounds, on yoga mats sitting on a beach by a tranquil river.

Podcast Babbage

Are your new year’s resolutions backed by science?

Our podcast on science and technology. We examine the evidence behind intermittent fasting, melatonin tablets for jet lag and breathing techniques


Podcast The Intelligence

The rise of a far-right Austrian party bears out a regional trend

Also on the daily podcast: remembering Jean-Marie Le Pen and our series The World Ahead looks at Latin America’s unbanked

Podcast Drum Tower

Inside the mind of Xi Jinping

Our weekly podcast on China. This week, the ideologies and anxieties that shape the leader’s decisions

Podcast The Intelligence

Justin Trudeau’s time leading Canada comes to an inglorious end

Also on the daily podcast: Charlie Hebdo a decade after the massacre and our series The World Ahead series looks at AI-aided drug design